Cervical Cancer, Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal SCC, Hormone Receptor-positive Breast Cancer, Metastatic Castration-resistant Prostate Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer, SCCHN, Tissue Factor-Expressing Solid Tumors, Triple Negative Breast Cancer
Conditions
Keywords
ADC, Antibody drug conjugate, Tissue Factor, Auristatin, Nivolumab, bevacizumab
Brief summary
This is a Phase 1, open-label, multicenter, dose-escalation and expansion study evaluating the safety, tolerability, PK, pharmacodynamics, and clinical antitumor activity of XB002 administered IV q3w alone and in combination with nivolumab or bevacizumab to subjects with advanced solid tumors.
Interventions
DRUGXB002
IV administration of XB002
DRUGNivolumab
IV administration of Nivolumab
DRUGBevacizumab
IV administration of bevacizumab
Sponsors
Exelixis
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Dose-escalation followed by cohort-expansion in tumor-specific expansion cohorts
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Cytologically or histologically and radiologically confirmed solid tumor that is inoperable, locally advanced, metastatic, or recurrent. * Dose-Escalation Stage Cohorts A, AB, and AN: The subject has received at least one systemic standard life-prolonging therapy unless it does not exist, or available therapies are intolerable or no longer effective. * Cohort-Expansion Stage (Cohorts B - M, BN, FN and HN): The subject has received standard life-prolonging therapies unless they do not exist, or available therapies are intolerable or no longer effective. * Cohort-Expansion Stage Cohort B and BN (Non-small Cell Lung Cancer): Subjects with Stage IV NSCLC who have documented radiographic disease progression during or following their last systemic anticancer therapy. * Cohort-Expansion Stage Cohort D (Epithelial Ovarian Cancer): Subjects with high-grade serous ovarian cancer, including primary peritoneal cancer (PPC) and fallopian tube cancer (FTC) who have platinum-resistant disease following treatment with platinum-containing chemotherapy. * Cohort-Expansion Stage Cohort E (Cervical Cancer): Subjects with persistent, recurrent, or metastatic carcinoma of the uterine cervix who have documented radiographic disease progression during or following their last systemic anticancer therapy. * Cohorts F and FN (SCCHN): Subjects with head and neck cancer (squamous cell histology) who have documented radiographic disease progression during or following their last systemic anticancer therapy. Allowed primary tumor locations are oral cavity, oropharynx, hypopharynx, glottic larynx. Note: Excluded are subjects with primary tumor site of the nasopharynx. * Cohort G (Pancreatic Cancer): Subjects with pancreatic cancer (adenocarcinoma histology) who have documented radiographic disease progression during or following their last systemic anticancer therapy. * Cohort H (Esophageal SCC): Subjects with esophageal cancer (squamous cell histology) who have documented radiographic disease progression during or following their last systemic anticancer therapy. Note: subjects with esophageal adenocarcinoma and adenocarcinoma of gastroesophageal junction (GEJ) are excluded. * Cohort I (mCRPC): Subjects with metastatic, castration resistant adenocarcinoma of the prostate. Note: Neuroendocrine differentiation and other histological features are permitted if adenocarcinoma is the primary histology. * Cohort J (TNBC): Subjects with triple-negative (estrogen receptor negative \[ER-\]/progesterone receptor negative \[PR-\]/ human epidermal growth factor receptor 2 negative \[HER-2-\]) breast cancer who have documented radiographic disease progression during or following their last systemic anticancer therapy for inoperable locally advanced or metastatic disease. * Cohort K (HR + BC): Subjects with breast cancer that is hormone receptor-positive (ER+ and/or PR+) and HER-2-) and who have documented radiographic disease progression during or following their last systemic anticancer therapy for inoperable locally advanced or metastatic disease. * Cohort L (Endometrial Cancer): Subjects with locally advanced, recurrent or metastatic endometrial cancer who have documented radiographic disease progression during or following their last systemic anticancer therapy. * Cohort M (Tumor-Agnostic Tissue Factor-Expressing Solid Tumors): Subjects with solid tumors other than those designated in Cohorts B-L and those which express tissue factor. Participation in this cohort will be at selected sites and countries based on site feasibility assessment. * Expansion Cohorts: Subjects must have measurable disease per RECIST 1.1 as determined by the Investigator, except for subjects with prostate cancer without soft tissue disease and subjects with primary brain tumors. * Tumor tissue material collected no more than 3 years prior to consent, if possible. If archival tumor tissue is not available, a fresh tumor biopsy may be collected from subjects enrolled in the Dose-Escalation Stage and should be collected from subjects in the Cohort-Expansion Stage. * Recovery to baseline or ≤ Grade 1 severity (Common Terminology Criteria for Adverse Events version 5 \[CTCAE v5\]) from AEs. * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1. * Adequate organ and marrow function. * Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception. * Female subjects of childbearing potential must not be pregnant at screening.
Exclusion criteria
* Receipt of prior therapies as defined in study protocol * Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment. * Uncontrolled, significant intercurrent or recent illness. * Major surgery within 4 weeks before first dose of study treatment * Corrected QT interval calculated by the Fridericia formula (QTcF) \> 480 ms per electrocardiogram (ECG). * Pregnant or lactating females * Previously identified allergy or hypersensitivity to components of study treatment formulations or history of severe infusion-related reactions to monoclonal antibodies. * Another unresolved malignancy or a malignancy that is considered to be cured within 2 years before first dose of study treatment. Note: Subjects with superficial non-melanoma skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy within 2 years before first dose of study treatment are eligible.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose-Escalation Stage: MTD/recommended dose for XB002 | 18 months | To determine the MTD and/or RD for further evaluation of IV administration of XB002 alone and in combination therapy in subjects with advanced malignancies |
| Cohort-Expansion Stage: Objective Response Rate (ORR) | 12 months | To evaluate preliminary efficacy of XB002 when administered alone and in combination therapy by determining the ORR per RECIST 1.1 (or other applicable response criteria eg. RANO or PCWG3 criteria) as assessed by the Investigator |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tolerability of XB002 as evaluated dose intensity of the study treatment | 30 months | To evaluate the tolerability of XB002 through the evaluation of dose intensity of the study treatment |
| Maximum Plasma Concentration (Cmax) | 30 months | To evaluate the Cmax for XB002, total antibody, and free payload at scheduled visits over time |
| Trough Concentration (Ctrough) | 30 months | To evaluate the Ctrough of XB002, total antibody, and free payload at scheduled visits over time |
| Immunogenicity of XB002 | 30 months | To assess the immunogenicity of XB002 as measured by anti-drug antibody (ADA) analysis |
| Safety of XB002: Adverse Events | 30 months | To evaluate the safety of XB002 through the evaluation of incidence and severity of nonserious adverse events (AEs) and serious adverse events (SAEs) |
| Anti-tumor activity of XB002: Duration of Response (DOR) | 30 months | To evaluate the anti-tumor activity of XB002, as measured by DOR, per RECIST 1.1 (or other applicable response criteria eg. RANO or PCWG3 criteria) as assessed by the Investigator (dose escalation stage) or by a BIRC for selected cohorts (cohort expansion stage) |
| Anti-tumor activity of XB002: Progression Free Survival (PFS) | 30 months | To evaluate the anti-tumor activity of XB002, as measured by PFS, per RECIST 1.1 (or other applicable response criteria eg. RANO or PCWG3 criteria) as assessed by the Investigator (dose escalation stage) or by a BIRC for selected cohorts (cohort expansion stage) |
| Cohort-Expansion Stage: overall survival | 12 months | To evaluate overall survival |
| Anti-tumor activity of XB002: Objective Response Rate (ORR) | 30 months | To evaluate the anti-tumor activity of XB002, as measured by ORR, per RECIST 1.1 (or other applicable response criteria eg. RANO or PCWG3 criteria) as assessed by the Investigator (dose escalation stage) or by a BIRC for selected cohorts (cohort expansion stage). |
| Tolerability of XB002 as evaluated by the duration of exposure for the study | 30 months | To evaluate the tolerability of XB002 through the evaluation of duration of exposure for the study treatment |
Countries
Australia, Belgium, France, Italy, Netherlands, South Korea, Spain, United Kingdom, United States
Outcome results
None listed